Paeoniflorin ameliorates interferon-alpha-induced neuroinflammation and depressive-like behaviors in mice

Oncotarget

Volumn 8, Issue 5, 2017, Pages 8264-8282

  Li, Jianwei ^a   Huang, Shaohui ^a   Huang, Weiliang ^a   Wang, Wanshan ^a   Wen, Ge ^a   Gao, Lei ^a   Fu, Xiuqiong ^b   Wang, Mengmeng ^a   Liang, Weihai ^a   Kwan, Hiu Yee ^b   Zhao, Xiaoshan ^a   Lv, Zhiping ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

Amygdala; Depression; Interferon; Neuroinflammation; Paeoniflorin

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 9; MONOCYTE CHEMOTACTIC PROTEIN 1; PAEONIFLORIN; TUMOR NECROSIS FACTOR; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; AUTACOID; CYTOKINE; GLUCOSIDE; RECOMBINANT PROTEIN; TERPENE;

AMYGDALA; ANALYSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; BEHAVIOR ASSESSMENT; BRAIN LEVEL; C57BL 6 MOUSE; CELL DENSITY; CONTROLLED STUDY; CYTOKINE ARRAY ANALYSIS; DEPRESSION; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; MEDIAL PREFRONTAL CORTEX; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PROTEIN BLOOD LEVEL; VENTRAL HIPPOCAMPUS; ANIMAL; ANIMAL BEHAVIOR; BLOOD; BRAIN; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; ENCEPHALITIS; FOOD PREFERENCE; HIPPOCAMPUS; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PSYCHOLOGY; SWIMMING; TIME FACTOR;

AMYGDALA; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIDEPRESSIVE AGENTS; ASTROCYTES; BEHAVIOR, ANIMAL; BRAIN; CYTOKINES; DEPRESSION; DISEASE MODELS, ANIMAL; ENCEPHALITIS; FOOD PREFERENCES; GLUCOSIDES; HIPPOCAMPUS; INFLAMMATION MEDIATORS; INTERFERON ALPHA-2; INTERFERON-ALPHA; MALE; MICE, INBRED C57BL; MICROGLIA; MONOTERPENES; MOTOR ACTIVITY; PREFRONTAL CORTEX; RECOMBINANT PROTEINS; SWIMMING; TIME FACTORS;

EID: 85018920153     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.14160     Document Type: Article

References (64)

1. Platanias LC. Mechanisms of type-I-and type-II-interferonmediated signalling. Nat Rev Immunol. 2005;5:375-86
2. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB, Miller AH. Paroxetine for the prevention of depression induced by high-dose interferon alfa. New England Journal of Medicine. 2001;344:961-6
3. Udina M, Castellvi P, Moreno-Espana J, Navines R, Valdes M, Forns X, Langohr K, Solà R, Vieta E, Martín-Santos R. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry. 2012;73:1128-38
4. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology (Baltimore, Md). 2000;31:1207-11
5. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology (Baltimore, Md). 1997;26:112S-21S
6. Leutscher PD, Lagging M, Buhl MR, Pedersen C, Norkrans G, Langeland N, Mørch K, Färkkilä M, Hjerrild S, Hellstrand K, Bech P; NORDynamIC Group. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology (Baltimore, Md). 2010;52:430-5
7. Udina M, Hidalgo D, Navines R, Forns X, Sola R, Farre M, Capuron L, Vieta E, Martín-Santos R. Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry. 2014;75:e1113-21
8. Diez-Quevedo C, Masnou H, Planas R, Castellvi P, Gimenez D, Morillas RM, Martín-Santos R, Navinés R, Solà R, Giner P, Ardèvol M, Costa J, Diago M, Pretel J. Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72:522-8
9. Morasco BJ, Loftis JM, Indest DW, Ruimy S, Davison JW, Felker B, Hauser P. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial. Psychosomatics. 2010;51:401-8
10. Morasco BJ, Rifai MA, Loftis JM, Indest DW, Moles JK, Hauser P. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord. 2007;103:83-90
11. Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003;163:59-64
12. Loftis JM, Hauser P. Safety of the treatment of interferonalpha-induced depression. Psychosomatics. 2003;44:524-6
13. Wu PL, Liao KF, Peng CY, Pariante CM, Su KP. Manic episode associated with citalopram therapy for interferoninduced depression in a patient with chronic hepatitis C infection. Gen Hosp Psychiatry. 2007;29:374-6
14. Hoyo-Becerra C, Schlaak JF, Hermann DM. Insights from interferon-alpha-related depression for the pathogenesis of depression associated with inflammation. Brain Behav Immun. 2014;42:222-31
15. O'Leary OF, Cryan JF. A ventral view on antidepressant action: roles for adult hippocampal neurogenesis along the dorsoventral axis. Trends in pharmacological sciences. 2014;35:675-87
16. Hoyo-Becerra C, Liu Z, Yao J, Kaltwasser B, Gerken G, Hermann DM, Schlaak JF. Rapid Regulation of Depression-Associated Genes in a New Mouse Model Mimicking Interferon-alpha-Related Depression in Hepatitis C Virus Infection. Mol Neurobiol. 2015 ;52:318-29
17. Hayley S, Scharf J, Anisman H. Central administration of murine interferon-alpha induces depressive-like behavioral, brain cytokine and neurochemical alterations in mice: a mini-review and original experiments. Brain Behav Immun. 2013;31:115-27
18. Fanselow MS, Dong HW. Are the dorsal and ventral hippocampus functionally distinct structures? Neuron. 2010;65:7-19
19. Pan W, Banks WA, Kastin AJ. Permeability of the bloodbrain and blood-spinal cord barriers to interferons. J Neuroimmunol. 1997;76:105-11
20. Collins JM, Riccardi R, Trown P, O'Neill D, Poplack DG. Plasma and cerebrospinal fluid pharmacokinetics of recombinant interferon alpha A in monkeys: comparison of intravenous, intramuscular, and intraventricular delivery. Cancer Drug Deliv. 1985;2:247-53
21. Zheng LS, Kaneko N, Sawamoto K. Minocycline treatment ameliorates interferon-alpha-induced neurogenic defects and depression-like behaviors in mice. Front Cell Neurosci. 2015;9:5
22. Garden GA, Moller T. Microglia biology in health and disease. J Neuroimmune Pharmacol. 2006;1:127-37
23. Duseja R, Heir R, Lewitus GM, Altimimi HF, Stellwagen D. Astrocytic TNFalpha regulates the behavioral response to antidepressants. Brain Behav Immun. 2015;44:187-94
24. Lieberman AP, Pitha PM, Shin HS, Shin ML. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci U S A. 1989;86:6348-52
25. Shoji Shibata MN. Studies on the Constituents of Japanese and Chinese Crude Drugs. VIII. Paeoniflorin, A Glucoside of Chinese Paeony Root.(1). Chemical and Pharmaceutical Bulletin. 1963;11:372-8
26. Zhu X, Jing L, Chen C, Shao M, Fan Q, Diao J, Liu Y, Lv Z, Sun X. Danzhi Xiaoyao San ameliorates depressive-like behavior by shifting toward serotonin via the downregulation of hippocampal indoleamine 2,3-dioxygenase. J Ethnopharmacol. 2015;160:86-93
27. Jing LL, Zhu XX, Lv ZP, Sun XG. Effect of Xiaoyaosan on major depressive disorder. Chin Med. 2015;10:18
28. Zhu X, Xia O, Han W, Shao M, Jing L, Fan Q, Liu Y, Diao J, Lv Z, Sun X. Xiao Yao San Improves Depressive-Like Behavior in Rats through Modulation of beta-Arrestin 2-Mediated Pathways in Hippocampus. Evid Based Complement Alternat Med. 2014;2014:902516
29. Qiu FM, Zhong XM, Mao QQ, Huang Z. Antidepressantlike effects of paeoniflorin on the behavioural, biochemical, and neurochemical patterns of rats exposed to chronic unpredictable stress. Neurosci Lett. 2013;541:209-13
30. Qiu F, Zhong X, Mao Q, Huang Z. The antidepressant-like effects of paeoniflorin in mouse models. Exp Ther Med. 2013;5:1113-6
31. Nam KN, Yae CG, Hong JW, Cho DH, Lee JH, Lee EH. Paeoniflorin, a monoterpene glycoside, attenuates lipopolysaccharide-induced neuronal injury and brain microglial inflammatory response. Biotechnol Lett. 2013;35:1183-9
32. Li P, Li Z. Neuroprotective effect of paeoniflorin on HO-induced apoptosis in PC12 cells by modulation of reactive oxygen species and the inflammatory response. Exp Ther Med. 2015;9:1768-72
33. Zhang Y, Li H, Huang M, Huang M, Chu K, Xu W, Zhang S, Que J, Chen L. Paeoniflorin, a Monoterpene Glycoside, Protects the Brain from Cerebral Ischemic Injury via Inhibition of Apoptosis. Am J Chin Med. 2015;43:543-57
34. Dong H, Li R, Yu C, Xu T, Zhang X, Dong M. Paeoniflorin inhibition of 6-hydroxydopamine-induced apoptosis in PC12 cells via suppressing reactive oxygen speciesmediated PKCdelta/NF-kappaB pathway. Neuroscience. 2015;285:70-80
35. Zhang HR, Peng JH, Cheng XB, Shi BZ, Zhang MY, Xu RX. Paeoniflorin Atttenuates Amyloidogenesis and the Inflammatory Responses in a Transgenic Mouse Model of Alzheimer's Disease. Neurochem Res. 2015;40:1583-92
36. Jiang C, Xu L, Chen L, Han Y, Tang J, Yang Y, Zhang G, Liu W. Selective suppression of microglial activation by paeoniflorin attenuates morphine tolerance. Eur J Pain. 2015;19:908-19
37. Zheng YB, Xiao GC, Tong SL, Ding Y, Wang QS, Li SB, Hao ZN. Paeoniflorin inhibits human gastric carcinoma cell proliferation through up-regulation of microRNA-124 and suppression of PI3K/Akt and STAT3 signaling. World J Gastroenterol. 2015;21:7197-207
38. Ping F, Shang J, Zhou J, Zhang H, Zhang L. 5-HT(1A) receptor and apoptosis contribute to interferon-alphainduced "depressive-like" behavior in mice. Neurosci Lett. 2012;514:173-8
39. Luo YW, Xu Y, Cao WY, Zhong XL, Duan J, Wang XQ, Hu ZL, Li F, Zhang JY, Zhou M, Dai RP, Li CQ. Insulin-like growth factor 2 mitigates depressive behavior in a rat model of chronic stress. Neuropharmacology. 2015;89:318-24
40. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl). 1985;85:367-70
41. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther. 1977;229:327-36
42. Zheng LS, Hitoshi S, Kaneko N, Takao K, Miyakawa T, Tanaka Y, Xia H, Kalinke U, Kudo K, Kanba S, Ikenaka K, Sawamoto K. Mechanisms for Interferon-alpha-Induced Depression and Neural Stem Cell Dysfunction. Stem Cell Reports. 2014;3:73-84
43. Capuron L, Miller AH. Cytokines and psychopathology: Lessons from interferon-a. Biological Psychiatry. 2004;56:819-24
44. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DB, Rustgi V, Jones EA. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med. 1987;147:1577-80
45. Hodes GE, Kana V, Menard C, Merad M, Russo SJ. Neuroimmune mechanisms of depression. Nat Neurosci. 2015;18:1386-93
46. Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience. 2013;246:199-229
47. Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10:1387-94
48. Kim SU, de Vellis J. Microglia in health and disease. J Neurosci Res. 2005;81:302-13
49. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature reviews Neuroscience. 2007;8:57-69
50. Furuyashiki T. Roles of dopamine and inflammation-related molecules in behavioral alterations caused by repeated stress. J Pharmacol Sci. 2012;120:63-9
51. Wu XB, Liang B, Gao YJ. The increase of intrinsic excitability of layer V pyramidal cells in the prelimbic medial prefrontal cortex of adult mice after peripheral inflammation. Neurosci Lett. 2016;611:40-5
52. Zheng C, Zhang T. Synaptic plasticity-related neural oscillations on hippocampus-prefrontal cortex pathway in depression. Neuroscience. 2015;292:170-80
53. Bagot RC, Parise EM, Pena CJ, Zhang HX, Maze I, Chaudhury D, Persaud B, Cachope R, Bolaños-Guzmán CA, Cheer JF, Deisseroth K, Han MH, Nestler EJ. Ventral hippocampal afferents to the nucleus accumbens regulate susceptibility to depression. Nature communications. 2015;6:7062
54. Koolschijn PC, van Haren NE, Lensvelt-Mulders GJ, Hulshoff Pol HE, Kahn RS. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Human brain mapping. 2009;30:3719-35
55. Muscatell KA, Dedovic K, Slavich GM, Jarcho MR, Breen EC, Bower JE, Irwin MR, Eisenberger NI. Greater amygdala activity and dorsomedial prefrontal-amygdala coupling are associated with enhanced inflammatory responses to stress. Brain Behav Immun. 2015;43:46-53
56. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14:36-49
57. Wynn TA. Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol. 2015;15:271-82
58. Kwilasz AJ, Grace PM, Serbedzija P, Maier SF, Watkins LR. The therapeutic potential of interleukin-10 in neuroimmune diseases. Neuropharmacology. 2015;96:55-69
59. De La Garza RN, Asnis GM, Pedrosa E, Stearns C, Migdal AL, Reinus JF, Paladugu R, Vemulapalli S. Recombinant human interferon-alpha does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:781-92
60. Loftis JM, Hauser P, Macey TA, Lowe JD. Can rodents be used to model interferon-alpha-induced depressive symptoms? Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:1364-5
61. Makino M, Kitano Y, Komiyama C, Hirohashi M, Takasuna K. Involvement of central opioid systems in human interferon-alpha induced immobility in the mouse forced swimming test. Br J Pharmacol. 2000;130:1269-74
62. Daducci A, Tambalo S, Fiorini S, Osculati F, Teti M, Fabene PF, Corsi M, Bifone A, Sbarbati A, Marzola P. Manganeseenhanced magnetic resonance imaging investigation of the interferon-alpha model of depression in rats. Magn Reson Imaging. 2014;32:529-34
63. Siddegowda NK, Kumar RN, Andrade C. Development of a murine animal model of depression for repeated dosing with human interferon alpha. Indian J Psychiatry. 2011;53:239-43. doi:10.4103/0019-5545.86815
64. Shuto H, Kataoka Y, Horikawa T, Fujihara N, Oishi R. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res. 1997;747:348-51